| Identification | Back Directory | [Name]
SCH 58261 | [CAS]
160098-96-4 | [Synonyms]
CS-2187
SCH-58261;SCH 58261
Butanoicacid,4-bromo-5-oxo-,ethylester
2-(Furan-2-yl)-7-phenethyl-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyriMidin-5-aMine
7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(2-phenylethyl)-
4-(furan-2-yl)-10-(2-phenylethyl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,7,11-pentaen-7-amine
4-(furan-2-yl)-10-(2-phenylethyl)-3,5,6,8,10,11-hexaazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2,4,7,11-pentaen-7-amine | [Molecular Formula]
C18H15N7O | [MDL Number]
MFCD00933778 | [MOL File]
160098-96-4.mol | [Molecular Weight]
345.365 |
| Chemical Properties | Back Directory | [Melting point ]
223 °C | [density ]
1.54±0.1 g/cm3(Predicted) | [storage temp. ]
Store at RT | [solubility ]
DMSO: >10 mg/mL, soluble
| [form ]
solid
| [pka]
2.78±0.30(Predicted) | [color ]
off-white
|
| Hazard Information | Back Directory | [Uses]
SCH 58261 is a potent and selective A2A adenosine receptor antagonist. | [Definition]
ChEBI: LSM-3822 is a member of triazolopyrimidines. | [Biological Activity]
Potent and selective A 2A adenosine receptor competitive antagonist (K i = 1.3 nM). Displays 323-, 53- and 100-fold selectivity over A 1 , A 2B and A 3 receptors, respectively. | [Biochem/physiol Actions]
SCH 58261 reduces the levels of TNF-α, Fas-L, Bax expression and activation of JNK-MAPK pathway. It has neuroprotective effects as it reduces demyelination of the neurons. SCH 58261 increases the concentration of secretion of dopamine and elicits locomotor sensitization, an attractive option in the possible treatment of Parkinson′s disease. | [storage]
Store at RT |
|
|